Abstracts tagged "Animal models"

Abstract Number: 392 • 2017 ACR/ARHP Annual Meeting
Effects of Synthetic Dmards on the Insulin Resistance and Obesity Associated with Rheumatoid Arthritis: An Obese Mouse Model of Arthritis
Nuria Barbarroja¹, Ivan Arias de la Rosa², Miriam Ruiz-Ponce¹, Sergio Rodriguez-Cuenca³, Maria Carmen Abalos-Aguilera², Yolanda Jiménez-Gómez¹, Patricia Ruiz-Limon², Carlos Perez-Sanchez¹, Eduardo Collantes-Estévez¹, Antonio Vidal-Puig³, Alejandro Escudero-Contreras² and Chary Lopez-Pedrera¹, ¹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Addenbroke’s Hospital, University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Numerous studies have demonstrated the closely association between rheumatoid arthritis (RA) and metabolic complications such as obesity and insulin resistance (IR). Thus, there is…
Abstract Number: 1074 • 2017 ACR/ARHP Annual Meeting
High Cholesterol Levels By ApoE Defenciency Reduce Bone Destruction in Murine Antigen-Induced Arthritis Via Inhibition of Osteoclastogenesis
Giuliana Ascone¹, Irene Di Ceglie¹, Arjen B. Blom¹, Birgitte Walgreen², Annet W. Sloetjes¹, Peter M. van der Kraan¹, Ernst Lindhout³, Mike Martens³ and Peter L. van Lent⁴, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Experimental, Radboud university medical center, Nijmegen, Netherlands, ³Future Diagnostics Solutions (FDs), Wijchen, Netherlands, ⁴Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by immune complex- deposition in the synovium, leading to increased bone destruction. In RA, joint…
Abstract Number: 1793 • 2017 ACR/ARHP Annual Meeting
Interleukin-17 Is Not a Determinant for the Pro- or Anti-Inflammatory Character of Interleukin-22 in Experimental Arthritis
Debbie M. Roeleveld¹, Loreto Parga Vidal², Monique M. Helsen², Birgitte Walgreen³, Bianka Marklein⁴, Karl Skriner⁵, Martin Hegen⁶, Peter L. van Lent², Fons A.J. van de Loo², Wim B. van den Berg², Peter M. van der Kraan² and Marije I. Koenders², ¹Experimental Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ²Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ³Experimental, Radboud university medical center, Nijmegen, Netherlands, ⁴Humboldt University and Free University, Berlin, Germany, ⁵Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ⁶Inflammation and Immunology Research Unit, Pfizer, Cambridge, MA
Background/Purpose: High interleukin-22 (IL-22) levels are detected in serum and synovial fluid of rheumatoid arthritis (RA) patients and have been shown to positively correlate with…
Abstract Number: 393 • 2017 ACR/ARHP Annual Meeting
The Role of Follicular Helper 17 T Cells in Glucose-6-Phosphate Isomerase Induced Arthritis
Izumi Kurata, Isao Matsumoto, Atsumu Osada, Hiroshi Ebe, Hoshimi Kawaguchi, Yuya Kondo, Hiroto Tsuboi and Takayuki Sumida, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Follicular helper T (Tfh) cell is a novel T cell subset which promotes follicular B cell activation, differentiation to plasma cell and antibody production.…
Abstract Number: 1319 • 2017 ACR/ARHP Annual Meeting
TAS05567 Is a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor That Attenuates Disease Severity in Animal Models of Autoimmune Diseases
Hiroaki Hayashi, Ryuusuke Kaneko, Manabu Tayama, Shunsuke Demizu, Daichi Akasaka, Hiroki Irie, Aki Kawagishi, Yoshio Ogino, Teruhiro Utsugi, Eiji Sasaki and Yoshikazu Iwasawa, TAIHO PHARMACEUTICAL CO., LTD., Tsukuba, Japan
Background/Purpose: Spleen tyrosine kinase (Syk) is a non-receptor cytoplasmic tyrosine kinase. B-cell receptor (BCR) and Fc receptor-mediated syk signaling pathways lead to activation of several…
Abstract Number: 1794 • 2017 ACR/ARHP Annual Meeting
Overexpression of Interleuk-22 Induces Expression of the Negative Immune-Regulator SOCS3 and Potently Reduces Collagen-Induced Arthritis in Mice
Debbie M. Roeleveld¹, Monique M. Helsen², Birgitte Walgreen³, Elly Vitters², Fons A.J. van de Loo², Peter L. van Lent², Wim B. van den Berg², Peter M. van der Kraan² and Marije I. Koenders², ¹Experimental Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ²Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ³Experimental, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: High interleukin-22 (IL-22) levels are detected in serum and synovial fluid of rheumatoid arthritis (RA) patients and have been shown to positively correlate with…
Abstract Number: 394 • 2017 ACR/ARHP Annual Meeting
Female Tumor Necrosis Factor Transgenic Mice Have More Severe Arthritis Than Males and Supporessed Levels of Bifidobacterium Pseudolongum in Their Gut Microbiome
Emily Wu¹, Richard Bell², Alex Grier³, Steven Gill⁴, Edward Schwarz⁵ and Homaira Rahimi⁶, ¹Department of Immunology, Microbiology, and Virology, University of Rochester, Rochester, NY, ²Center for Musculoskelatal Research, University of Rochester, Rochester, NY, ³Rochester Genomics Center, University of Rochester, Rochester, NY, ⁴Genomics Research Center, University of Rochester, Rochester, NY, ⁵Orthopedeatrics, University of Rochester, Rochester, NY, ⁶Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) has an increased prevalence and severity in women compared to men, yet the underlying etiology of this sexual dimorphism is unknown.…
Abstract Number: 1320 • 2017 ACR/ARHP Annual Meeting
TAS5315, a Novel Bruton’s Tyrosine Kinase Inhibitor, Ameliorates Inflammation and Bone Erosion in Murine Model for Rheumatoid Arthritis
Yohei Yoshiga¹, Fumihito Hosoi¹, Satoru Iguchi¹, Ryuusuke Kaneko², Yoshinori Nakachi¹, Daichi Akasaka², Kenji Tanaka², Kazuhiko Yonekura², Teruhiro Utsugi², Eiji Sasaki² and Yoshikazu Iwasawa², ¹TAIHO PHARMACEUTICAL CO., LTD., TSUKUBA, Japan, ²TAIHO PHARMACEUTICAL CO., LTD., Tsukuba, Japan
Background/Purpose: The erosions of bone and cartilage are a cardinal feature of rheumatoid arthritis (RA) and associated with disease severity and poor functional outcome. Although…
Abstract Number: 1833 • 2017 ACR/ARHP Annual Meeting
iRhom2 Deficiency Protects Fcgr2b-/- Lupus-Prone Mice from Kidney Damage By Modulating ADAM17-Dependent Shedding of TNF-α and EGFR Ligand
Xiaoping Qing¹, Yurii Chinenov², Patricia M. Redecha³, Michael Madaio⁴, Priya Issuree⁵, David McIlwain⁶, Tak Mak⁷, Carl Blobel⁵ and Jane E. Salmon⁸, ¹Program in Inflammation and Autoimmunity, Hospital for Special Surgery, New York, NY, ²Arthritis & Tissue Degeneration Program, Hospital for Special Surgery, New York, NY, ³Autoimmunity & Inflammation, Hospital for Special Surgery, New York, NY, ⁴Medicine, Medical College of Georgia, Augusta, GA, ⁵Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, New York, NY, ⁶Department of Microbiology and Immunology, Stanford University, Stanford, CA, ⁷Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Center, Toronto, ON, Canada, ⁸Medicine/Rheumatology, Hospital of Special Surgery, New York, NY
Background/Purpose: A disintegrin and metalloprotease 17 (ADAM17) controls ecto-domain shedding of TNFα and epithelial-growth factor ligands (EGFR) such as heparin-binding EGF (HB-EGF). TNFa and HB-EGF…
Abstract Number: 396 • 2017 ACR/ARHP Annual Meeting
Phospho-STAT1 Inhibition Is the Initial Step after Tofacitinib Treatment in Rabbits with Severe Chronic Synovitis
Sandra Pérez-Baos, Paula Gratal, Juan Ignacio Barrasa, Ana Lamuedra, Gabriel Herrero-Beaumont and Raquel Largo, Bone and Joint Research Unit, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain
Background/Purpose: Tofacitinib (TOFA) is a Janus Kinase (Jak) inhibitor approved for the treatment of rheumatoid arthritis (RA) 1. It has recently been shown to selectively…
Abstract Number: 1323 • 2017 ACR/ARHP Annual Meeting
Crucial Roles for Toll-like Receptor 9 in the Pathogenesis of Erosive Autoimmune Arthritis and during Osteoclastogenesis
Anita Fischer¹, Brigitte Meyer¹, Birgit Niederreiter², Erik Lönnblom³, Rikard Holmdahl⁴ and Günter Steiner², ¹Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²Rheumatology, Medical University of Vienna, Vienna, Austria, ³Department of Medical Biochemistry & Biophysics, Karolinska Institute, Stockholm, Sweden, ⁴Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Release and insufficient removal of endogenous nucleic acids may be involved in triggering harmful autoimmune reactions important in the initiation of systemic autoimmune diseases…
Abstract Number: 1910 • 2017 ACR/ARHP Annual Meeting
ERAP1 Deficiency Implicates Long Peptides in Protection from HLA-B27-Induced Experimental Spondyloarthritis
Tri Tran¹, Tejpal Gill¹, Joshua R. Bennett¹, Vance Holt¹, Sohee Hong², Joel Taurog³ and Robert Colbert¹, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²National Institutes of Arthritis and Muskuloskeletal and skin diseases, National Institutes of Health, Bethesda, MD, ³Dept Int Med-Rheum Dis Div, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Common endoplasmic reticulum (ER) aminopeptidase 1 (ERAP1) haplotypes influence the risk of developing axial spondyloarthritis (SpA) in HLA-B27-positive individuals, with loss-of-function and reduced expression…
Abstract Number: 398 • 2017 ACR/ARHP Annual Meeting
An on-Demand Drug Delivery System for the Treatment of Inflammatory Arthritis
Jing Yan¹, Nitin Joshi², Seth Levy², Sachin Bhagchandani², Kai Slaughter², Nicholas Sherman¹, Julian Amirault², Xueyin He², Tan Shi Rui², Michael Valic², Praveen Vemula³, Oscar Miranda², Oren Levy², Antonios Aliprantis⁴, Joerg Ermann¹ and Jeffrey Karp², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Institute for Stem Cell Biology and Regenerative Medicine (inStem), Bangalore, India, ⁴Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Many types of inflammatory arthritis (IA) are treated with systemic therapy. In situations where only one or a few joints are active, intra-articular drug…
Abstract Number: 1324 • 2017 ACR/ARHP Annual Meeting
Angiotensin II Type I Receptor Deficiency Exacerbates Erosive Bone Destruction of hTNF-Transgenic Arthritis Mice
Takafumi Mito¹, Tomoyuki Mukai¹, Shunichi Fujita¹, Shoko Kodama¹, Akiko Nagasu¹, Teruki Sone² and Yoshitaka Morita¹, ¹Department of Rheumatology, Kawasaki Medical School, Kurashiki, Okayama, Japan, ²Department of Nuclear Medicine, Kawasaki Medical School, Kurashiki, Okayama, Japan
Background/Purpose: Angiotensin II (Ang II) is known to function on various organs including kidneys, adrenal glands as well as the nervous and cardiovascular systems through…
Abstract Number: 1929 • 2017 ACR/ARHP Annual Meeting
Sustained Efficacy of Intra-Articular SB-061, a Novel Matrix Regulator Inspired By Aggrecan, in a Rat Model of Osteoarthritis
Kate Stuart¹, Julia Chen¹, Sharmi Saha¹, Harsha Kabra¹, Athene Chan¹, Kamal Egodoge¹, Jennifer Oskins², Chaohua Lin², Morten Karsdal³, Mark Chambers² and John Paderi¹, ¹Symic Bio, Emeryville, CA, ²Lilly Research Laboratories, Indianapolis, IN, ³Biomarkers and Reseacrh, Nordic Bioscience, Herlev, Denmark
Background/Purpose: No therapy for osteoarthritis (OA) has yet to deliver both structural and symptomatic benefits. Symic is approaching this unmet clinical need with a novel…

« Previous Page
1
…
4
5
6
7
8
…
25
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].